Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms-Reference-Cited by-同舟云学术

Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms

Published:2024-08-15 Issue:1 Volume:22 Page:
ISSN:1478-811X
Container-title:Cell Communication and Signaling
language:en
Short-container-title:Cell Commun Signal

Author:

Du Kai-Xin,Wu Yi-Fan,Hua Wei,Duan Zi-Wen,Gao Rui,Liang Jun-Heng,Li Yue,Yin Hua,Wu Jia-Zhu,Shen Hao-Rui,Wang Li,Shao Yang,Li Jian-Yong,Liang Jin-Hua,Xu Wei^ORCID

Funder

Jiangsu Science and Technology Department

China Postdoctoral Science Foundation

Jiangsu Province Hospital (the First Affiliated Hospital with Nanjing Medical University) Clinical Capacity Enhancement Project

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12964-024-01765-w.pdf

Reference42 articles.

1. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med May. 2018;24(5):679–90. https://doi.org/10.1038/s41591-018-0016-8.

2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nat Feb. 2000;3(6769):503–11. https://doi.org/10.1038/35000501.

3. Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncology: Official J Am Soc Clin Oncol Nov. 2011;1(31):4079–87. https://doi.org/10.1200/jco.2011.35.4423.

4. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood May. 2011;5(18):4836–43. https://doi.org/10.1182/blood-2010-12-322362.

5. Molina TJ, Canioni D, Copie-Bergman C et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d’Etudes des Lymphomes de l’Adulte/lymphoma study association phase III trial LNH 03-2B. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Dec 10. 2014;32(35):3996–4003. https://doi.org/10.1200/jco.2013.54.9493